Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

被引：0

作者：

Di Giacomo, A. M. ^{[1
]}

Simonetti, E. ^{[2
]}

Calabro, L. ^{[3
]}

Vegni, V. ^{[4
]}

Santangelo, F. ^{[5
]}

Depenni, R. ^{[6
]}

Colucci, M. ^{[2
]}

Valente, M. ^{[5
]}

Grifoni, R. ^{[7
]}

Lofiego, M. F. ^{[2
]}

Amato, G. ^{[5
]}

Keer, H. N. ^{[8
]}

Oganesian, A. ^{[8
]}

Chan, D. ^{[8
]}

Giannarelli, D. ^{[9
]}

Altomonte, M. ^{[5
]}

Ceccarelli, M. ^{[10
,11
]}

Anichini, A. ^{[12
]}

Covre, A. ^{[2
]}

Maio, M. ^{[1
]}

机构：

[1] Univ Siena, Univ Hosp Siena, NIBIT Fdn Onlus, Ctr Immunooncol,Oncol, Siena, Italy

[2] Univ Siena, Med Oncol, Siena, Italy

[3] Univ Ferrara, Med Oncol, Ferrara, Italy

[4] NIBIT Fdn Onlus, Radiol, Siena, Italy

[5] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy

[6] Univ Modena, Med Oncol, Modena, Italy

[7] Azienda USL Toscana Centro, Med Oncol, Florence, Italy

[8] Taiho Pharmaceut Inc, Clin Dev, Pleasanton, CA USA

[9] Fdn Policlin Gemelli, Biostat, Rome, Italy

[10] Univ Miami, Miller Sch Med, Computat Biol, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL USA

[12] Fdn IRCCS Ist Nazl Tumori, Expt Oncol, Human Tumors Immunobiol Unit, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2288

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA47

引用

页码：1237 / 1237

页数：1

共 50 条

[1] Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
Pedersen, Jesper Geert
Sokac, Mateo
Sorensen, Boe Sandahl
Luczak, Adam Andrzej
Aggerholm-Pedersen, Ninna
Birkbak, Nicolai Juul
Ollegaard, Trine Heide
Jakobsen, Martin Roelsgaard
CANCERS, 2022, 14 (14)
[2] Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Di Giacomo, A. M.
Sileni, V. Chiarion
Del Vecchio, M.
Ferrucci, P. F.
Guida, M.
Quaglino, P.
Guidoboni, M.
Marchetti, P.
Cutaia, O.
Amato, G.
Gambale, E.
Calabro, L.
Valente, M.
Danielli, R.
Giannarelli, D.
Mandala, M.
Maio, M.
ANNALS OF ONCOLOGY, 2020, 31 : S734 - S734
[3] A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
Page, D. B.
Kaur, L.
Hong, E. C. C.
Su, A.
Moxon, N.
Mellinger, S.
Kelly, T.
Kelley, A.
Fredrich, N.
Seino, A.
Liberatore, G.
Conlin, A. K.
Topp, Z.
Perlewitz, K.
Stanton, S.
Wu, Y.
Traina, T. A.
Gucalp, A.
ANNALS OF ONCOLOGY, 2024, 35 : S379 - S380
[4] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
Ari VanderWalde
Shay L. Bellasea
Kari L. Kendra
Nikhil I. Khushalani
Katie M. Campbell
Philip O. Scumpia
Lawrence F. Kuklinski
Frances Collichio
Jeffrey A. Sosman
Alexandra Ikeguchi
Adrienne I. Victor
Thach-Giao Truong
Bartosz Chmielowski
David C. Portnoy
Yuanbin Chen
Kim Margolin
Charles Bane
Constantin A. Dasanu
Douglas B. Johnson
Zeynep Eroglu
Sunandana Chandra
Egmidio Medina
Cynthia R. Gonzalez
Ignacio Baselga-Carretero
Agustin Vega-Crespo
Ivan Perez Garcilazo
Elad Sharon
Siwen Hu-Lieskovan
Sapna P. Patel
Kenneth F. Grossmann
James Moon
Michael C. Wu
Antoni Ribas
Nature Medicine, 2023, 29 : 2278 - 2285
[5] Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
VanderWalde, Ari
Bellasea, Shay L.
Kendra, Kari L.
Khushalani, Nikhil I.
Campbell, Katie M.
Scumpia, Philip O.
Kuklinski, Lawrence F.
Collichio, Frances
Sosman, Jeffrey A.
Ikeguchi, Alexandra
Victor, Adrienne I.
Truong, Thach-Giao
Chmielowski, Bartosz
Portnoy, David C.
Chen, Yuanbin
Margolin, Kim
Bane, Charles
Dasanu, Constantin A.
Johnson, Douglas B.
Eroglu, Zeynep
Chandra, Sunandana
Medina, Egmidio
Gonzalez, Cynthia R.
Baselga-Carretero, Ignacio
Vega-Crespo, Agustin
Garcilazo, Ivan Perez
Sharon, Elad
Hu-Lieskovan, Siwen
Patel, Sapna P.
Grossmann, Kenneth F.
Moon, James
Wu, Michael C.
Ribas, Antoni
NATURE MEDICINE, 2023, 29 (09) : 2278 - +
[6] Phase 1 study to evaluate safety and efficacy of ipilimumab plus nivolumab plus external beam radiotherapy in patients with metastatic melanoma.
Postow, Michael Andrew
Knox, Susan Jane
McCabe, Danielle
Macri, Mary J.
Schwarzenberger, Paul
Ricciardi, Toni
Ryan, Aileen
Venhaus, Ralph Rudolph
Barker, Christopher Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[7] Interim analysis of a phase II study of nivolumab/ipilimumab plus cabozantinib in patients with unresectable advanced melanoma
Gibney, Geoffrey Thomas
Pecora, Andrew L.
Rapisuwon, Suthee
Chen, Kevin
Gardner, Kellie
Cramer, Gayle
Blair, Danielle
Avergas, Amy
Swanson, Nicole
Ahn, Jaeil
Atkins, Michael B.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[8] A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma
Shalhout, Sophia Z.
Emerick, Kevin S.
Kaufman, Howard L.
Silk, Ann W.
Thakuria, Manisha
Miller, David M.
JOURNAL OF IMMUNOTHERAPY, 2022, 45 (07) : 299 - 302
[9] A phase II, open label, randomized controlled trial of nivolumab plus ipilimumab with stereotactic radiotherapy versus ipilimumab plus nivolumab alone in patients with melanoma brain metastases (ABC -X Trial).
Gonzalez, Maria
Hong, Angela M.
Carlino, Matteo S.
Atkinson, Victoria
Wang, Wei
Lo, Serigne
Brown, Michael Paul
Foote, Matthew C.
Pinkham, Mark B.
Le, Hien
Roos, Daniel E.
Osorio, Monica
Haghighi, Neda
Kok, David
Postow, Michael A.
McArthur, Grant A.
Menzies, Alexander M.
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[10] Partial Response to Ipilimumab plus Nivolumab after Onset of nephrotic Syndrome under PD-1 Monotherapy
Glutsch, V.
Graen, F.
Weber, J.
Gesierich, A.
Goebeler, M.
Schilling, B.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 36 - 36

← 1 2 3 4 5 →